Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$21.32 - $34.81 $2.17 Million - $3.54 Million
101,612 New
101,612 $2.97 Million
Q2 2023

Aug 10, 2023

SELL
$21.38 - $29.19 $1.67 Million - $2.28 Million
-78,003 Reduced 39.32%
120,363 $3.41 Million
Q1 2023

May 11, 2023

BUY
$21.74 - $30.93 $4.01 Million - $5.7 Million
184,341 Added 1314.37%
198,366 $4.56 Million
Q4 2022

Feb 13, 2023

BUY
$24.81 - $31.52 $347,960 - $442,068
14,025 New
14,025 $394,000
Q3 2022

Nov 10, 2022

SELL
$19.51 - $34.14 $1.18 Million - $2.06 Million
-60,238 Closed
0 $0
Q2 2022

Aug 19, 2022

SELL
$17.06 - $31.42 $1.81 Million - $3.34 Million
-106,221 Reduced 63.81%
60,238 $1.34 Million
Q1 2022

May 13, 2022

BUY
$26.68 - $34.81 $4.14 Million - $5.41 Million
155,287 Added 1389.97%
166,459 $4.85 Million
Q4 2021

Feb 11, 2022

SELL
$29.58 - $49.78 $408,381 - $687,262
-13,806 Reduced 55.27%
11,172 $367,000
Q3 2021

Nov 15, 2021

BUY
$41.92 - $58.18 $880,990 - $1.22 Million
21,016 Added 530.44%
24,978 $1.15 Million
Q2 2021

Aug 16, 2021

SELL
$52.06 - $61.27 $3.37 Million - $3.96 Million
-64,711 Reduced 94.23%
3,962 $218,000
Q1 2021

May 17, 2021

SELL
$44.23 - $57.5 $129,505 - $168,360
-2,928 Reduced 4.09%
68,673 $3.55 Million
Q4 2020

Feb 16, 2021

BUY
$33.21 - $46.54 $1.39 Million - $1.95 Million
41,829 Added 140.5%
71,601 $3.1 Million
Q3 2020

Nov 16, 2020

SELL
$33.87 - $55.93 $1.02 Million - $1.69 Million
-30,136 Reduced 50.3%
29,772 $1.04 Million
Q2 2020

Aug 14, 2020

BUY
$34.45 - $53.48 $2.06 Million - $3.2 Million
59,908 New
59,908 $3.2 Million
Q2 2019

Aug 14, 2019

SELL
$46.17 - $68.1 $582,711 - $859,490
-12,621 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$45.92 - $67.67 $579,556 - $854,063
12,621 New
12,621 $851,000

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $2.9B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.